The drug will be manufactured at the group’s formulation manufacturing facility at Ahmedabad SEZ, India
The acquisition is for an enterprise value of Rs. 218 crores
Revenue from operations for the half year was Rs. 178.5 crore, declined by 23% whereas net profit for the half year was Rs. 16.9 crore, declined by 70%
Drospirenone Tablets (RLD Slynd) had estimated annual sales of US $141 million in the US
Ketorolac Tromethamine is advised for the short-term management of moderately severe acute pain in adult patients
Saroglitazar Mg is an investigational compound in the USA/EU, undergoing Phase 2b/3 clinical trials in patients with Primary Biliary Cholangitis and Phase 2b in patients with Non- alcoholic Steatohepatitis
The company has reported total income of Rs. 703.3 crores during the period ended September 30, 2022
Glenmark’s Sodium Phenylbutyrate Tablets USP, 500 mg, will be distributed in the U.S. by Glenmark Pharmaceuticals USA.
The expansion program includes investments in France and the U.S., adding an additional 23,000+ m² of manufacturing footprint.
Subscribe To Our Newsletter & Stay Updated
